| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CNTNAP1 |
| Uniprot No | P78357 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-356aa |
| 氨基酸序列 | DEELVGPLYARSLGASSYYSLLTAPRFARLHGISGWSPRIGDPNPWLQIDLMKKHRIRAVATQGSFNSWDWVTRYMLLYGDRVDSWTPFYQRGHNSTFFGNVNESAVVRHDLHFHFTARYIRIVPLAWNPRGKIGLRLGLYGCPYKADILYFDGDDAISYRFPRGVSRSLWDVFAFSFKTEEKDGLLLHAEGAQGDYVTLELEGAHLLLHMSLGSSPIQPRPGHTTVSAGGVLNDQHWHYVRVDRFGRDVNFTLDGYVQRFILNGDFERLNLDTEMFIGGLVGAARKNLAYRHNFRGCIENVIFNRVNIADLAVRRHSRITFEGKVAFRCL |
| 预测分子量 | 53.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CNTNAP1重组蛋白的示例参考文献(注：以下内容为示例性概括，实际文献需通过学术数据库查询)：
---
1. **标题**: *"Recombinant CNTNAP1 extracellular domain production and its role in neuronal adhesion"*
**作者**: Smith J, et al.
**摘要**: 该研究通过哺乳动物表达系统成功表达了CNTNAP1的胞外结构域重组蛋白，并验证其与Contactin-1的相互作用。实验表明重组CNTNAP1在体外促进神经元细胞的粘附，为研究轴突髓鞘化机制提供了工具。
---
2. **标题**: *"Structural and functional characterization of CNTNAP1 using recombinant protein technology"*
**作者**: Lee H, et al.
**摘要**: 作者利用昆虫细胞系统表达并纯化全长CNTNAP1重组蛋白，结合X射线晶体学解析其部分结构域的三维构象。功能实验揭示CNTNAP1在神经突触组装中的潜在作用，为相关疾病机制研究奠定基础。
---
3. **标题**: *"CNTNAP1 mutations disrupt protein function: Insights from recombinant mutant protein analysis"*
**作者**: Garcia R, et al.
**摘要**: 研究构建了携带致病突变的CNTNAP1重组蛋白，发现突变导致蛋白稳定性下降及与配体结合能力丧失，解释了CNTNAP1缺陷相关周围神经病变的分子机制。
---
4. **标题**: *"Development of a CNTNAP1 recombinant antigen for autoimmune neuropathy diagnostics"*
**作者**: Wang Y, et al.
**摘要**: 通过原核表达系统制备CNTNAP1重组抗原，用于检测患者血清中的自身抗体。实验证实该抗原在诊断慢性炎性脱髓鞘性多发性神经病(CIDP)中具有高特异性。
---
**提示**：实际研究中建议通过PubMed或Google Scholar以关键词“CNTNAP1 recombinant protein”或“CNTNAP1 expression”检索最新文献，并关注其与神经系统疾病或结构生物学相关的应用。
CNTNAP1 (Contactin-associated protein 1) is a member of the neurexin superfamily, primarily known for its role in cell adhesion and nervous system development. It encodes a single-pass transmembrane protein that interacts with contactins, a group of glycosylphosphatidylinositol (GPI)-anchored cell adhesion molecules, to mediate neuron-glia interactions. Structurally, CNTNAP1 contains extracellular F58-type domains, epidermal growth factor (EGF)-like repeats, a transmembrane region, and a cytoplasmic tail. These features enable its involvement in myelination, particularly in the formation and maintenance of the paranodal junctions in myelinated axons. These junctions are critical for saltatory conduction of nerve impulses and axonal integrity.
Recombinant CNTNAP1 protein is engineered in vitro using expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, functional protein for research and therapeutic applications. Its production often involves cloning the CNTNAP1 gene into expression vectors, followed by transfection, protein purification, and validation via techniques like Western blot or mass spectrometry. Recombinant CNTNAP1 retains the ability to bind contactins and other partners, making it valuable for studying molecular mechanisms in neurodevelopment and demyelinating disorders.
Mutations in CNTNAP1 are linked to severe neurodevelopmental conditions, including hypomyelinating leukodystrophy and peripheral neuropathy, characterized by impaired nerve signaling. Research using recombinant CNTNAP1 has advanced understanding of paranodal junction assembly, axoglial interactions, and disease pathways. It also serves as a tool for drug screening, antibody development, and exploring therapeutic strategies for disorders like Charcot-Marie-Tooth disease. Ongoing studies aim to elucidate its role in neuropsychiatric conditions, leveraging recombinant protein models to bridge molecular insights with clinical outcomes.
×
